Shihui Ma

Dr. Shihui Ma

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2025 in Oncologie
Verified
Journal Article
Open access
PDF file
ZWZongwen Wu
Zongwen Wu
DWDina Wu
Dina Wu
CHChengsheng Huang
Chengsheng Huang
JZJinhua Zhang
Jinhua Zhang
SSShijun Sun
Shijun Sun
SMShihui Ma
Shihui Ma
Objectives: PCSK9 is critical in cholesterol homeostasis and anti-tumor immunity modulation. This study aims to investigate PCSK9’s role in HER2-positive breast cancer (BC) as a potential prognostic marker. Methods: The impact of PCSK9 on HER2-positive BC was analyzed by virtue of data from The Cancer Genome Atlas (TCGA). Moreover, PCSK9 expression in tumor cells from 92 HER2-positive patients was assessed through immunohistochemistry (IHC). Then, it was found that this expression was correlated with various clinicopathological parameters including histological grading, hormone receptor (HR) status, and patient survival. Results: PCSK9 expression positively correlated with pathohistological grading and hormone receptor status, but negatively with patient survival. GSEA showed low PCSK9 expression groups enriched in immune-related pathways, while high expression groups favored coagulation pathways. CIBERSORT analysis revealed a notable negative association between PCSK9 expression and γδ T cells, suggesting PCSK9’s role in modulating tumor microenvironment (TME) immune reactivity. Low PCSK9 expression was associated with a more favorable response to neoadjuvant therapy in patients. Conclusions: PCSK9 expression in HER2-positive BC is a significant prognostic indicator, with higher levels related to worse clinical outcomes. These results suggest PCSK9’s potential utility in predicting treatment responses and guiding therapeutic strategies for HER2-positive BC patients.

6 August 2025 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
ZGZibai Guo
Zibai Guo
JWJinhong Wei
Jinhong Wei
AGAnping Gui
Anping Gui
XLXuanhua Liang
Xuanhua Liang
PYPengli Yu
Pengli Yu
SMShihui Ma
Shihui Ma
Background: Response to trastuzumab-based neoadjuvant therapy in human epidermal growth factor receptor type 2 (HER2)-positive breast cancer is affected by multiple features of the tumor. Few studies have investigated epigenetic features in these patients. This study investigates whether changes in deoxyribonucleic acid (DNA) methylation patterns are linked to response to neoadjuvant therapy in HER2-positive breast cancer and aims to identify epigenetic markers of treatment resistance.Methods: 28 tumor samples were obtained from 20 HER2-positive breast cancer patients treated with neoadjuvant therapy: 12 from patients who achieved pathological complete response (pCR) before treatment, and 8 from patients who did not (non-pCR). For the non-pCR group, matched post-treatment samples were also collected, enabling paired pre- and post-treatment comparisons. After whole-genome methylation sequencing of all samples, the methylation differences between the pre-treatment pCR and non-pCR groups, as well as the methylation differences in non-pCR groups between pre-treatment and post-treatment samples were compared.Results: Before treatment, tumors in the non-pCR group showed slightly more hypomethylation events compared to the pCR group. After treatment, the same non-pCR tumors showed increased hypermethylation. Notably, immune-related pathways in these tumors were found to be hypermethylated, suggesting possible immune dysregulation. Methylation changes in the oncogenes MOS and RET were associated with potential resistance mechanisms. Additionally, four genes—KIT, LAD1, FAM110C, and DAPP1—were identified as candidate resistance markers based on their altered methylation patterns.Conclusions: These findings highlight how DNA methylation changes may influence treatment outcomes in HER2-positive breast cancer and suggest novel epigenetic markers that could help predict or overcome therapy resistance.

12 August 2026 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
XLXuanhua Liang
Xuanhua Liang
ZGZibai Guo
Zibai Guo
JWJinhong Wei
Jinhong Wei
AGAnping Gui
Anping Gui
MJMengru Jian
Mengru Jian
SMShihui Ma
Shihui Ma
Background: Neratinib, an irreversible pan-HER tyrosine kinase inhibitor, is a well-established extended adjuvant therapy for early-stage human epidermal growth factor receptor 2-positive (HER2+) breast cancer. However, its clinical application is often constrained by the high incidence of treatment-related diarrhea. This study sought to assess the dynamic changes in health-related quality of life (HRQoL) and the tolerability of neratinib, with a particular focus on dose escalation strategies and anti-diarrheal prophylaxis, within a real-world Chinese patient cohort. Methods: This single-center, prospective observational study included 31 female patients diagnosed with stage I-III HER2-positive breast cancer who initiated neratinib therapy following the completion of trastuzumab-based adjuvant treatment between October 2022 and January 2024. Patients were administered either non–dose-escalation group (240 mg/day) or dose-escalation group (120 mg/160 mg daily during Week 1, 160 mg/200 mg daily during Week 2, and 240 mg daily from Week 3 onward). Diarrhea management was conducted using prophylactic or on-demand loperamide. HRQoL was evaluated longitudinally through the EQ-5D-5L (health utility index and EQ visual analog scale [EQ VAS]) and Functional Assessment of Chronic Illness Therapy-Diarrhea (FACIT-D) questionnaires at predefined time points: baseline (D1), D30, D60, D90, D180, and D360. Diarrhea severity was graded according to Common Terminology Criteria for Adverse Events v5.0 (CTCAE v5.0) criteria. Statistical analyses encompassed descriptive statistics and Wilcoxon signed-rank tests. Results: The median age of the patients was 48 years (range: 37–65 years), with 58.1% and 41.9% classified as pathological stage II and III, respectively. A total of 64 diarrhea events were recorded (grade 1, 48.4%; grade 2, 50.0%; grade 3, 1.6%), with no grade 4 events or fatalities. Permanent discontinuation of treatment due to diarrhea occurred in 16.1% of patients, 23.5% in the dose-escalation group vs. 7.1% in the non-dose-escalation group. HRQoL temporarily declined during the early treatment phase, as evidenced by a reduction in the EQ-5D-5L health utility index from 0.96 ± 0.07 at baseline to 0.89 ± 0.15 at D30 (p=0.011) and a decrease in the EQ VAS score from 89.94 ± 9.92 to 84.16 ± 12.64 at D30 (p=0.018). However, HRQoL demonstrated progressive recovery from D90 onward, with scores surpassing baseline levels by D180 (EQ-5D-5L utility index: 0.96 ± 0.07; EQ VAS: 89.92 ± 7.74) and D360 (utility index: 0.97 ± 0.06; EQ VAS: 92.84 ± 7.19). The FACIT-D score showed an initial improvement (baseline: 58.81 ± 7.95 vs. D30: 66.90 ± 11.39, p=0.002), followed by stabilization at baseline levels from D180 onward. Notably, no disease recurrence or distant metastasis was observed in patients who completed the treatment. Conclusions: Neratinib-associated HRQoL impairment is transient, with initial declines primarily due to diarrhea, which typically resolves within 3–6 months of treatment. With the implementation of appropriate supportive measures, such as loperamide prophylaxis and dose modifications, the majority of patients experience sustained HRQoL recovery, and even improvement, over a 12-month period.